Sanofi SA (NYSE:SNY) was the recipient of unusually large options trading on Tuesday. Stock investors bought 651 put options on the company. This is an increase of 666% compared to the typical volume of 85 put options.
Several hedge funds have recently added to or reduced their stakes in SNY. Deutsche Bank AG grew its holdings in shares of Sanofi by 369.7% in the fourth quarter. Deutsche Bank AG now owns 1,462,947 shares of the company’s stock valued at $62,903,000 after acquiring an additional 1,151,455 shares in the last quarter. Fisher Asset Management LLC grew its holdings in shares of Sanofi by 3.0% in the fourth quarter. Fisher Asset Management LLC now owns 14,500,758 shares of the company’s stock valued at $623,533,000 after acquiring an additional 418,501 shares in the last quarter. Renaissance Group LLC bought a new position in shares of Sanofi in the third quarter valued at approximately $16,239,000. Senzar Asset Management LLC grew its holdings in shares of Sanofi by 25.4% in the fourth quarter. Senzar Asset Management LLC now owns 999,786 shares of the company’s stock valued at $42,990,000 after acquiring an additional 202,300 shares in the last quarter. Finally, OLD Mission Capital LLC grew its holdings in shares of Sanofi by 250.4% in the fourth quarter. OLD Mission Capital LLC now owns 280,376 shares of the company’s stock valued at $12,056,000 after acquiring an additional 200,355 shares in the last quarter. 8.94% of the stock is owned by institutional investors.
Sanofi (NYSE:SNY) opened at $40.40 on Wednesday. The stock has a market capitalization of $100,880.00, a P/E ratio of 16.63, a PEG ratio of 2.15 and a beta of 0.92. The company has a quick ratio of 1.26, a current ratio of 1.70 and a debt-to-equity ratio of 0.25. Sanofi has a twelve month low of $38.14 and a twelve month high of $50.65.
The firm also recently announced an annual dividend, which will be paid on Monday, June 4th. Stockholders of record on Thursday, May 10th will be issued a $1.8609 dividend. The ex-dividend date of this dividend is Wednesday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.58. This represents a dividend yield of 4.72%. Sanofi’s dividend payout ratio is currently 45.27%.
A number of brokerages have commented on SNY. Sanford C. Bernstein reissued a “market perform” rating and set a $45.00 price objective (down from $50.00) on shares of Sanofi in a report on Thursday, February 8th. ValuEngine lowered Sanofi from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research lowered Sanofi from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Bank of America lowered Sanofi from a “buy” rating to a “neutral” rating in a report on Wednesday, December 6th. Finally, TheStreet lowered Sanofi from a “b-” rating to a “c+” rating in a report on Tuesday, February 13th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the stock. Sanofi has an average rating of “Hold” and an average target price of $49.33.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3261109/traders-buy-high-volume-of-put-options-on-sanofi-sny.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.